| 000 | 01710 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516113206.0 | ||
| 264 | 0 | _c20130124 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-012-1975-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEl-Bakly, Wesam M | |
| 245 | 0 | 0 |
_a6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cDec 2012 |
||
| 300 |
_a833-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aCaspase 3 _xmetabolism |
| 650 | 0 | 4 |
_aCatechols _xadministration & dosage |
| 650 | 0 | 4 |
_aCreatine Kinase, MB Form _xmetabolism |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aFatty Alcohols _xadministration & dosage |
| 650 | 0 | 4 |
_aHeart _xdrug effects |
| 650 | 0 | 4 |
_aHeart Diseases _xblood |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aInfusions, Parenteral |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardium _xmetabolism |
| 650 | 0 | 4 |
_aNF-kappa B _xmetabolism |
| 650 | 0 | 4 | _aOxidative Stress |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred Strains |
| 650 | 0 | 4 | _aReceptor for Advanced Glycation End Products |
| 650 | 0 | 4 |
_aReceptors, Immunologic _xmetabolism |
| 700 | 1 | _aLouka, Manal L | |
| 700 | 1 | _aEl-Halawany, Ali M | |
| 700 | 1 | _aSchaalan, Mona F | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 70 _gno. 6 _gp. 833-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-012-1975-y _zAvailable from publisher's website |
| 999 |
_c22137911 _d22137911 |
||